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                                                  ABSTRACT 
 
Background and objectives: Laparoscopic appendicectomy is associated with 
an appreciably high rate of intra operative haemodynamic instability associated 
with pneumoperitonium. This study is designed to compare the effectiveness of 
Esmolol and Clonidine for maintenance of intra operative hemodynamic 
stability in laproscopic appendicectomy. 
 
Methods: In a randomized, double blind study, 30 patients of both sexes 
received Esmolol 0.5 mg/kg bolus before induction followed by infusion of 
100µ/kg/min and 30 patients received infusion of Clonidine 3µ/kg in 100 ml 
normal saline 15 min before induction and 30 patients received a placebo of 100 
ml normal saline before induction. Peri operative anaesthetic care was 
standardized in all patients. Patients were then observed for intra operative pulse 
rate, blood pressure. 
 
Results: Esmolol and clonidine groups were found to have significantly lower 
heart rate and blood pressure during the intra operative period as compared to 
control group. 
 
  
Conclusion: Both Esmolol and Clonidine produces hemodynamic stability for 
laproscopic appendicectomy, with more reduction in heart rate and blood 
pressure with Esmolol than Clonidine. 
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                                            INTRODUCTION 
 
 Laparoscopic surgeries have revolutionized surgeries and it has now become 
the “gold standard” of many surgical procedures, and has been promoted, as a 
“gentle surgery”. However, this procedure is not risk free. In fact it produces 
significant haemodynamic changes specially in elderly and haemodynamically 
compromised patients.  
 
Pneumoperitoneum(Pnp) affects several homeostatic systems leading to 
alteration in acid-base balance, cardiovascular, pulmonary physiology and stress 
response. The extent of cardiovascular changes associated with 
pneumoperitoneum include an increase in mean arterial pressure decrease in 
cardiac output and increase in systemic vascular resistance which in turn 
compromise tissue perfusion.  
 
Various pharmacological agents were chosen to prevent haemodynamic changes 
associated with pneumoperitoneum. Nitroglycerine was used to correct the 
reduction of cardiac output associated with increased pulmonary occlusion 
pressure and systemic vascular resistance. 
 
Esmolol, an ultra short-acting cardio-selective ß1-receptor antagonist, has been 
shown to blunt haemodynamic responses to perioperative noxious stimuli. 
  
Clonidine inhibits the release of catecholamine and vasopressin and thus 
modulates the haemodynamic changes induced by pneumoperitoneum. 
 
Considering all these observations, the present study was designed to evaluate 
the type and extent of haemodynamic changes associated with laparoscopic 
surgery and also to find out the efficacy of clonidine and Esmolol in prevention 
of such haemodynamic changes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                 AIM AND OBJECTIVES OF THE STUDY 
 
 
PRIMARY OBJECTIVE 
 
To compare the effectiveness of Esmolol and clonidine for maintaining 
hemodynamic stability in laproscopic appendicetomy 
 
 
SECONDARY OBJECTIVES 
• To determine any adverse effects in the postoperative period. 
• To determine the postoperative nausea and  vomiting , analgesic  requirement 
and sedation in each group  
 
 
 
 
 
 
 
 
 
 
        
 
           
 
 
 
  
 
LAPAROSCOPIC APPENDICECTOMY 
 
Laparoscopic surgeries are done very commonly nowadays in every parts of the 
world. They have many advantages compared to an open procedure like less 
surgical trauma, less intraoperative and postoperative pain, early discharge, and 
above all the cosmetic benefit. It requires the creation of a pneumoperitonium. 
CO2 is used for gas insufflation via a VERESS needle, at a rate of 1-6 litre 
/minute, to a pressure of 14-20mmhg. Intraoperative problems during 
laparoscopic surgery can be cardiovascular, respiratory, gastrointestinal, renal 
or metabolic related. Hemodynamic changes, decrease in venous return, reflux 
tachycardia and arrhythmias due to gas insufflation are the main cardiovascular 
problems. Respiratory problems are mainly due to pneumoperitonium, which 
may cause cephalad displacement of diaphragm. This leads to reduction in lung 
volumes including tidal volume, functional residual capacity, decreased 
pulmonary compliance, increased airway resistance, and also the risk of 
barotrauma during IPPV. Restriction in diaphragmatic mobility promotes 
uneven distribution of ventilation to the nondependent part of the lung, which 
can lead to ventilation- perfusion mismatch with hypoxemia and hypercarbia. 
(CO2 absorption from pneumoperitonium may also cause hypercarbia). For this 
reason ETCO2 (End tidal CO2) monitoring is very much desirable during 
  
laparoscopic surgeries. Increased intra abdominal pressure may predispose to 
regurgitation and aspiration in those who are susceptible.                                   
Gastrointestinal considerations during laparoscopic appendicectomy are mainly 
regarding injuries to the visceral organs that can be caused by the laparoscopic 
instruments. Trochar insertion can damage viscera; particularly a stomach 
distended by hand ventilation. There is increased incidence of nausea and 
vomiting after laparoscopic appendicectomy. (Incidence of up to 70% has been 
reported in some studies). Though the exact cause for this is not known residual 
pneumoperitonium is considered the main etiology. Intra-abdominal pressure 
>20mmhg adversely affects renal function and urine output. Renal blood flow 
and glomerular filtration rate decrease because of increase in renal vascular 
resistance, reduction in glomerular filtration gradient and decrease in cardiac 
output. Complications of gas insufflation can be arrhythmias, subcutaneous 
emphysema, pneumomediastinum, pneumopericardium, pneumothorax and 
venous gas embolism. In the preanaesthetic checkup, cardiac and respiratory 
function is assessed carefully. General anaesthesia with muscle paralysis 
intubation and IPPV is the most common method. If appropriate, general 
anaesthesia with spontaneous ventilation by using laryngeal mask airway can 
also be considered for ASA 1 or 2 patients with no other contraindications. 
Ventilatory pattern is adjusted according to respiratory and hemodynamic 
response of the patient. Large tidal volumes (12-15ml/kg) prevent progressive 
microatelectasis and hypoxemia and allows for more effective alveolar 
  
ventilation and CO2 elimination. However peak airway pressure is monitored to 
check excessive increase. Nitrous oxide does not adversely affect surgical 
conditions during laparoscopic appendicectomy by causing bowel distension 
and does not increase the incidence of PONV. Isoflurane is the volatile 
anaesthetic of choice because it is less arrhythmogenic and cause less 
myocardial depression. Postoperative recovery is usually very rapid. PONV can 
be particularly troublesome after laparoscopic appendicectomy. Pain consists of 
an early transient vague abdominal and shoulder discomfort. Pain from trochar-
puncture wounds are usually mild. Use of opioids should be accompanied by an 
antiemetic. Pulmonary function is better preserved following laparoscopic 
appendicectomy than in open appendicectomy. 
 
                         
 
 
 
 
  
                Hemodynamic Problems During Laparoscopy 
Hemodynamic changes observed during laparoscopy result from the combined 
effects of pneumoperitoneum, patient position, anaesthesia, and hypercapnia 
from the absorbed CO2. In addition to these pathophysiologic changes, reflex 
increases of vagal tone and arrhythmias can also develop. 
Peritoneal insufflation to IAPs higher than 10 mm Hg induces significant 
alterations of hemodynamics. These disturbances are characterized by decreases 
in cardiac output, increased arterial pressures, and elevation of systemic and 
pulmonary vascular resistances. Heart rates remain unchanged or increased only 
slightly. The decrease in cardiac output is proportional to the increase in IAP. 
Cardiac outputs, which decrease shortly after the beginning of the peritoneal 
insufflation, subsequently increase, probably as a result of surgical stress. 
The mechanism of the decrease of cardiac output is multifactorial. A decrease in 
venous return is observed after a transient increase in venous return at low IAPs 
(<10 mm Hg).  Increased IAP results in caval compression, pooling of blood in 
the legs, and an increase in venous resistance. The decline in venous return, 
which parallels the decrease in cardiac output, is confirmed by a reduction in 
left ventricular end-diastolic volume measured using transesophageal 
echocardiography. Cardiac filling pressures, however, rise during peritoneal 
insufflation. The paradoxical increase of these pressures can be explained by the 
  
increased intrathoracic pressure associated with pneumoperitoneum.  Right 
atrial pressure and pulmonary artery occlusion pressure can no longer be 
considered reliable indices of cardiac filling pressures during 
pneumoperitoneum. The fact that atrial natriuretic peptide concentrations 
remain low despite increased pulmonary capillary occlusion pressure during 
pneumoperitoneum further suggests that abdominal insufflation interferes with 
venous return. The reduction in venous return and cardiac output can be 
attenuated by increasing circulating volume before the pneumoperitoneum is 
produced. Increased filling pressures can be achieved by fluid loading or tilting 
the patient to a slight head-down position before peritoneal insufflation, by 
preventing the pooling of blood with intermittent sequential pneumatic 
compression device, or by wrapping the legs with elastic bandages. 
The ejection fraction of the left ventricle, assessed by echocardiography, does 
not appear to decrease significantly when IAP increases to 15 mm Hg. 
However, all studies describe an increase in systemic vascular resistance during 
the existence of the pneumoperitoneum. This increase in afterload is not a reflex 
sympathetic response to the decreased cardiac output. Systemic vascular 
resistance was reported to be increased in studies where no decrease in cardiac 
output was found. Although the normal heart tolerates increases in afterload 
under physiologic conditions, the increases in afterload produced by the 
  
presence of a pneumoperitoneum can be deleterious to patients with cardiac 
disease. 
The increase in systemic vascular resistance is affected by patient position. The 
trendelenburg position attenuates this increase; the head-up position aggravates 
it. The increase in systemic vascular resistance can be corrected by the 
administration of vasodilating anesthetic agents, such as isoflurane or direct 
vasodilating drugs, such as nitroglycerin or nicardipine. 
The increase in systemic vascular resistance is thought to be mediated by 
mechanical and neurohumoral factors. The return of hemodynamic parameters 
to baseline values is gradual, taking several minutes, suggesting the 
involvement of neurohumoral factor(s). Catecholamines, the renin-angiotensin 
system, and especially vasopressin are all released during the presence of the 
pneumoperitoneum and may contribute to increasing the afterload. However, 
only the time course of vasopressin release parallels that of the increase in 
systemic vascular resistance. Increases in plasma vasopressin concentrations 
correlate with changes in intrathoracic pressure and transmural right atrial 
pressure. Mechanical stimulation of peritoneal receptors also results in 
increased vasopressin release, systemic vascular resistance, and arterial 
pressure. However, whether increasing IAP to 14 mm Hg is sufficient to 
stimulate these receptors is unknown. The increase in systemic vascular 
resistance also explains why the arterial pressure increases but the cardiac 
  
output falls. Use of α2-adrenergic agonists such as clonidine or 
dexmedetomidine  and of β-blocking agents significantly reduces hemodynamic 
changes and anaesthetic requirements. Use of high doses of remifentanil almost 
completely prevents the hemodynamic changes. 
 
 
 
 
 
 
                                      
 
 
 
 
 
  
 
 
 
 
 
 
  ESMOLOL 
  
                         PHARMACOLOGY OF ESMOLOL 
In 1982 ZAROSLINSKI described the concept of an utra short acting β- 
adrenergic blocker. From this work esmolol which is a cardioselective β-blocker 
that has an extremely short duration of action was subsequently identified and 
characterised. 
Chemistry 
Esmolol (ASL – 8052) is chemically methyl 3- [4-(2-hydroxy-3-
(isopropylamino)propoxy] phenyl propionate HCl, a molecular structure 
characteristic of second generation B-blockers. Esmolol contains an ester in the 
para position of phenyl ring. The presence and location of the ester is of 
fundamental importance in the determination of Esmolol`s   cardioselectivity as 
well as its ultra short action. 
Esmolol has the empirical formula C16H26NO4C1 and a molecular weight of 
331.8 . It has one asymmetric centre and exists as an enentiomeric pair. 
Esmolol hydrochloride is a white to off white crystalline powder. IT is a 
relatively hydrophilic compound which is very soluble in H2O and freely 
soluble in alcohol. 
Clinical pharmacology 
Esmolol hydrochloride is a β1-selective (cardioselective) adrenergic receptor 
blocking agent with rapid onset, a very short duration of action and no 
  
significant intrinsic sympathomimetic or membrane stabilising activity at 
therapeutic dose. It inhibits the β1 receptors located chiefly in cardiac muscles, 
but their preferential effect is not absolute and at higher doses it begins to 
inhibit β2 receptors located chiefly in the bronchial and vascular musculature. 
Esmolol is 43 fold more potent at β-receptors in the atria (β1) than in trachea 
(β2). Blockade of vascular β-receptors required a dose several fold greater than 
that required for cardiac β – blockade. Esmolol does not have any effect on 
peripheral vascular resistance. 
Pharmacokinetics and Metabolism 
Esmolol is rapidly metabolised by hydrolysis of ester linkage, chiefly by 
esterase in the cytosol of red blood cells and not by plasma cholineesterases or 
red cell membrane acetylcholinesterase. Total body clearance in man was found 
to be 20 L/kg/hr which is greater than cardiac output. Thus the metabolism of 
Esmolol is not limited by the rate of blood flow to the metabolising tissues such 
as the liver and kidney. It has a rapid distribution half-life of about 2 minutes 
and an elimination half life of about 9 minutes. 
After an appropriate loading dose, a steady state blood level of Esmolol are 
obtained within 5 minutes. Steady state is obtained within 30 minutes, without 
the loading dose. Steady state blood levels are maintained during infusion (20 
min). Since it has a short half life, blood levels can be rapidly altered by 
increasing or decreasing the infusion rate. 
  
Metabolism of Esmolol results in formation of an acidic metabolite (ALS-8123) 
phenyl propionic acid and methanol. The acidic metabolite has 1/1500th the 
activity of Esmolol and its blood levels do not correspond to the level of β 
blockade. Acid metabolite has an elimination half life of about 3.7 hrs and is 
excreted in urine with a clearance approximately equal to the glomerular 
filtration rate. Elimination of acid metabolite is significantly decreased in 
patients with renal disease with the elimination half life increased to tenfold that 
of normal. Esmolol is unaffected by plasma cholinesterase. For full enzymatic 
activity, the Esmolol esterase in RBC cytosol requires a heat labile high 
molecular weight plasma component. The enzyme is not inhibited to any 
significant degree of cholinesterase inhibitor such as physostigmine or 
echothiophate, but is totally inhibited by sodium fluride. No metabolic 
interaction has been observed between esmolol and other ester containing 
molecules of clinical relevance. It does not modify the magnitude or duration of 
neuromuscular blockade in response to succinylcholine (Richard J. 
Gorzynski) esmolol is 55 % bound to human plasma protein while acid 
metabolite is only 10% bound. 
In human electrophysiological studies esmolol produced effects typical of a β- 
blocker; decreased heart rate , increase in sinus cycle length, prolongation of 
sinus node recovery time. 
 
  
1.Esmolol produces reduction in heart rate , systolic blood pressure, 
rate pressure product and right ventricular ejection fraction and cardiac index at 
rest and during exercise, similar in magnitude to propranolol, but produces 
significantly lower fall systolic in blood pressure; esmolol also produces small, 
clinically insignificant increase in left ventricular end-diastolic pressure and 
pulmonary capillary wedge pressure 30 min after discontinuation of infusion all 
the hemodynamic parameters return to pretreatment levels. 
2.Cardioselectivity of Esmolol was demonstrated by the infusion of Esmolol in 
asthmatic patients which produced no significant increase in specific airway 
resistance compared to placebo. Unlike Esmolol, propranolol produces 
significant bronchospasm requiring bronchodilator therapy. Esmolol shows no 
adverse effects in patients with COPD. 
3. Esmolol is very effective in the management of supraventricular tachycardia, 
atrial fibrillation and atrial flutter. 
There is significant decrease in blood pressure compared to propranolol but was 
rapidly reversible with decreased infusion rates or on discontinuation. 
Hypotension was less frequent in those patients receiving concomitant digoxin. 
Drug interaction                                                                            
Catecholamines depleting drugs (eg reserpine) may have an additive effect 
when given with Esmolol. So patients should be observed fro hypotension or 
  
marked bradycardia.Esmolol concentrations were higher when given with 
warfarin but this is of no clinical importance. When given with digoxin blood 
levels of digoxin were higher and when given with morphine blood levels of 
Esmolol were higher. 
Indications 
For rapid control of ventricular rate as in atrial flutter or fibrillation. 
For short term control of ventricular rate when short acting agents are desirable 
as in     (SVT, unstable angina , myocardial infarction) and to control 
perioperative tachycardia. 
Adverse Reactions 
CVS- Symptomatic hypotension occours in 12% of patients. Asymptomatic 
hypotension in 25% of patients. Hypotension gets resolved on discontinuation 
of treatment. Very rarely bradycardia, chest pain, syncope, sinus pause and 
asystole occour all reversible with discontinuation of treatment. 
CNS- Dizziness, Headache , agitation and fatigue 
RS-  Bronchospasm , nasal congestion – relative less 
Skin- Inflammation , and induration at the site of infusion , oedema, skin 
discolouration, thrombophlebitis and local skin necrosis. 
 
  
Acute Toxicity 
Accidental massive overdose when it occours due to an error in dilution. It can 
cause hypotension , bronchospasm , drowsiness, bradycardia and loss of 
consciousness. These are resolved within ten minutes of discontinuation or with 
administration of pressor agents. 
Compatible with commonly used intravenous fluids except NaHCO3 injection. 
Preparations Available 
100 mg  - 10 ml vial 
2.5 gm – 10 ml ampule 
Dosage 
To attenuate the sympathoadrenal response during laryngoscopy and intubation, 
the dosage is 1.5 mg/kg as a bolus or as an infusion at the rate of 500µg/ kg/ 
min for 2 minute as loading dose followed by a maintenance dose of 
100µg/kg/min 
To initiate treatment of a patient with supraventricular tachycardia, a loading 
dose of 500µg/ kg/min for 1 min for 4 minutes. If an adequate therapeutic effect 
is not observed within 5 min, the same loading dose can be repeated and 
followed with a maintenance infusion increased to 100 µg/ kg/min, therapeutic 
  
plasma level being 400- 1200 nano gm /ml. The time to 100% recovery is 30 
minutes. 
 
 
 
 
 
 
 
               
 
 
 
 
 
  
 
 
 
 
                                    CLONIDINE HYDROCHLORIDE 
 
  
               PHARMOCOLOGY OF CLONIDINE HYDROCHLORIDE 
Introduction:  
             Clonidine hydrochloride is a centrally acting selective partial alpha -2 
agonist introduced in early 1960s, it was during its use as a nasal decongestant 
that its anti- hypertensive property was found out. Subsequently more insights 
into the pharmacological properties have led to its use in clinical anaesthesia 
practice as well.  
          Clonidine hydrochloride is an imidazoline compound and exists as a 
mesomeric compound. The chemical name is 2-(2, 6- dichlorophenylamino)-2-
imidazoline hydrochloride. The structural formula is C9H9C12N3HCl. 
        The molecular weight is 266.56. Clonidine is an odourless, bitter, white, 
crystalline substance, soluble in alcohol and water. Clonidine improves the 
quality of anaesthesia, provides a more stable cardiovascular course during 
anaesthesia and reduces the dose requirement of the anaesthetic agent. In fact 
clonidine may reduce the halothane MAC by upto 50% in a dose dependent 
manner.  Clonidine potentiates the anaesthetic action of the local anaesthetics 
with fewer side effects in peripheral nerve blocks and central neuraxial 
blockade. 
 
 
  
Availability:   
 Available as one ml ampoule containing 150 micrograms. It should be stored 
below 25oc.  
 
Mechanism of action: 
        Clonidine is a centrally acting selective partial α2 adrenergic agonist with a 
selectivity ratio of 220: 1 in favour of α2 receptors.  The three subtypes of α2 
receptors are α2a, α2b, α2c. α2a receptors mediate  sedation, analgesia,  
sympatholysis . α2b receptors mediate vasoconstriction and anti- shivering. The 
startle response may reflect the activation of α2c receptors.   The drug is lipid 
soluble, penetrates the blood brain barrier to reach the hypothalamus and 
medulla when injected epidurally.  It stimulates the inhibitory α2 
adrenoreceptors to reduce the central neural transmission in the spinal neurons.  
Inhibition of substance- P release is believed to be involved in the analgesic 
effect. 
  The α2 adrenoreceptors are located on the afferent terminals of  both 
peripheral and spinal neurons in the superficial laminae of the spinal cord and 
within several brain stem nuclei implicated in analgesia.  The superficial 
laminae contain three group of neurons: tonic, adapting, single- spike firing, all 
of which receive their primary sensory input from Aδ and C fibres. Studies in 
  
rat models show that clonidine inhibits voltage gated Na+ and K+ channels and 
suppresses the generation of action potentials in tonic- firing spinal dorsal horn 
neurons, contributing to analgesic effect. 
            Another contribution to analgesic effect may be through the release of 
acetylcholine in the neuraxial region. The α2 adrenergic agonists also enhance 
analgesia from intraspinal opioids. Sedation is produced by its action on locus 
ceruleus.  
         Clonidine affects the blood pressure in a complex fashion after neuraxial 
or systemic administration because of opposing action at multiple sites.  In the 
nucleus tractus solitarius and locus ceruleus of the brain stem, activation of 
post- synaptic α2 adrenoreceptors reduces sympathetic drive. It also activates 
nor-adrenergic imidazoline preferring binding sites in the lateral reticular 
nucleus producing hypotension and anti- arrythmogenic action. In the periphery 
it acts on pre-synaptic α2 adrenoreceptors at sympathetic terminals reduces the 
release of nor-epinephrine causing vasorelaxation and reduced chronotropic 
drive. The brainstem and the peripheral effects of α2 adrenoreceptor stimulation 
are counterbalanced by the direct peripheral vasoconstriction through its action 
on α2 adrenoreceptors from the circulating concentrations of clonidine.  
    As a result the dose response for clonidine by neuraxial or systemic 
administration is U-shaped, with peripheral vasoconstriction from circulating 
drug concentrations at high doses opposing central sympatholysis. 
  
Pharmacodynamics: 
The analgesic effect of clonidine is more potent after neuraxial administration 
indicating a spinal site of action, favours neuraxial administration, though it is 
possible to achieve analgesia from systemic administration as well. 
General:  
Clonidine is observed to be approximately twice as potent given epidurally as 
intravenously. 
Cardiovascular system:  
Clonidine has minor or no effects on responses to vasoconstrictors or atropine 
given to treat hypotension or bradycardia respectively, that may occur with 
neuraxial anaesthesia. 
Sedation: 
This is a desired property. Clonidine produces a dose dependent sedation at the 
dose of 50 mics or more in less than 20 minutes regardless of the route of 
administration. 
Respiration:  
They don’t induce profound respiratory depression even after massive overdose 
nor do they potentiate respiratory depression from opioids. 
 
  
Peripheral nerves:   
It produces a minor degree of blockade at high concentrations with some 
preference for  
C- fibres in the peripheral nerves and this effect in part enhance the peripheral 
nerve block when added to local anaesthetics, probably because the 
α2adrenoreceptors are lacking on the axons of peripheral nerves. 
Pharmacokinetics; 
           Clonidine is well absorbed orally and is nearly 100% bio available. The 
mean half life of the drug in plasma is about 12 hours. It is excreted in an 
unchanged form by the kidney, and its half- life can dramatically increase in the 
presence of impaired renal function.  
A transdermal delivery system is available in which the drug is released at a 
constant rate for about a week. Three or four days are required to achieve steady 
state concentration. 
        Clonidine is highly lipid soluble and readily distributes into extra- vascular 
sites including the central nervous system. 
 300 micrograms intravenously over 10 min produces: 
    Distribution t ½    :    11 ± 9 minutes. 
  
    Elimination  t1/2    :   9 ± 2 hour,  41 hours in severe renal 
dysfunction. 
    Volume of distribution : 2.1 ± 0.4 l/kg 
    Plasma protein binding  : 20-40 % in vitro. 
    Metabolism   :  minor pathways with the major  
        metabolite , p- hydroxyclonidine. 
  Excretion:  
70% of the dose, mainly in the form of unchanged parent drug (40-60%) 
in urine. 
 So, the elimination t1/2 of clonidine varies as a function of  creatinine 
clearance.  In subjects undergoing hemodialysis only 5% of the body clonidine 
store was removed. 
Adverse effects:  
1. Body as a whole :  Weakness, fatigue, headache and withdrawal 
syndrome, pallor, a weakly positive coomb’s test and fever. 
2. Cardiovascular: palpitations, tachycardia, bradycardia about 5 in 1000,  
syncope, raynaud’s phenomenon, congestive heart failure, ECG abnormalities 
like sinus node arrest, junctional bradycardia, high degree AV block and 
arrhythmias are reported rarely.               
  
3. Central nervous system: nervousness, agitation, mental depression, 
insomnia, vivid dreams or night mares, anxiety, visual and auditory 
hallucinations have been reported rarely. 
4. Dermatological: rash, angioneurotic edema, pruritus, urticaria and 
alopecia rarely. 
5. Gastro intestinal tract: nausea and vomiting, anorexia, malaise, transient 
abnormalities in liver function tests, hepatitis, parotitis and constipation. 
6. Genitourinary:  decreased sexual activity, impotence, loss of libido, 
nocturia. 
7. Hematologic: thrombocytopenia rarely. 
8. Metabolic: weight gain and gynaecomastia, 
9. Musculoskeletal: muscle or joint pain, leg cramps. 
10.  Oro-otolaryngeal: dryness of the nasal mucosa. 
11.  Opthalmological: dryness, burning of eyes. 
Precautions: 
1. In patients with renal insufficiency , lower dose is needed.  
2.  Sudden withdrawal of prolonged continuous epidural infusion 
 produces hypertensive crisis. So it should be gradually discontinued over 
2 to 4 days. 
  
3. Use with caution  in patients with cerebrovascular or coronary 
insufficiency. 
4. When infused into upper thoracic spinal segments produces pronounced 
decrease in blood pressure. 
5. If a patient with beta blocker is on continuous epidural therapy, beta 
blocker should be withdrawn several days before discontinuation of 
epidural clonidine. 
6. Intrathecal / epidural clonidine often causes bradycardia that if 
symptomatic can be treated with inj. Atropine. 
Contraindications: 
1. Known hypersensitivity to clonidine or components of the product. 
2. In patients with bradyarrhythmia or AV block. 
3. Patients with severe cardiovascular disease 
4. Patients with cardiovascular / hemodynamic instability. 
5. Above C4 level is contraindicated because there are no safety data to 
support such use. 
Interactions:    
     1. Clonidine may potentiate the CNS- depressive effect of alcohol, 
barbiturates or  other sedative drugs. 
     2. Narcotics may potentiate the hypotensive effects of clonidine. 
  
     3. Tricyclic anti depressants may antagonize the hypotensive effects of 
clonidine. 
    4.  Concomitant administration of drugs with a negative chronotropic/ 
dromotropic effect (beta blockers, digoxin) can cause or potentiate 
bradycardiac rhythm disturbances. 
    5. Beta blockers may potentiate the hypertensive response seen with 
clonidine withdrawal. 
   6. Epidural clonidine may prolong the duration of pharmacologic effects of                    
epidural local anaesthetics, opioids, neostigmine and other drugs. 
 
Indications: 
1. To prolong the duration of epidural/ spinal anaesthesia and Peripheral 
nerve block 
 2. As adjuvant for the treatment of intra operative and post operative pain. 
 3. Treatment of intra articular intra operative and post operative pain. 
 4.  In epidural add on agent for relief of severe cancer pain. 
 5. As an anxiolytic. 
 6. For sedation. 
  
 7. To prevent or treat shivering.  
 8. Treatment of hypertensive crisis 
Anaesthetic uses: 
1. Premedication: acting on locus ceruleus produces sedation. Also got an 
anaesthesia- sparing effect. 
2. Control of hemodynamics: prevents hypertension and tachycardia during 
laryngoscopy and intubation as well as during surgical stimulation. 
Decreased incidence of myocardial ischemia in cardiac and vascular 
surgeries. 
4. Epidural: as a sole agent or in combination with opioids or local 
anaesthetics to provide excellent analgesia in labour analgesia. 
5. Spinal: with local anaesthetics clonidine improve the quality and duration 
of the block, minimize the tourniquet pain during lower limb surgery, and 
prevents shivering. 
6. Caudal:  with local anaesthetics increases the duration of anaesthesia and 
analgesia by 2 or 3 times without hemodynamic side effects. Dose 2-3 
mics/kg 
  
7. Peripheral nerve blocks:  prolongs the duration of anaesthesia and 
analgesia with local anaesthetics by two times in a dose of 75 to150 
micro grams. 
8. Bier’s block: 150 mics enhance the tolerance of tourniquet. 
9.  Intra articular analgesia. 
Overdosage and treatment: 
        There is no specific antidote for clonidine overdosage. Supportive 
measures like atropine, ephedrine, i.v fluids is enough.  For hypertensive crisis 
i.v furosemide, diazoxide, phentolamine can be used. 
          Yohimbine partially reverses the analgesia and sedation but not the BP 
and heart rate changes produced by the epidural clonidine. 
          Naloxone may be a useful adjunct for the management of clonidine 
induced respiratory depression, hypotension and or coma. 
 Blood pressure should be monitored after injecting naloxone as it may produce 
paradoxical hypertension. 
 
                                                                   
 
  
                                            REVIEW OF LITERATURE 
A number of clinical studies have been undertaken in the past to assess the 
efficacy of Esmolol and Clonidine on haemodynamic changes. 
 
1. Yuvesh Passi et al -J Anaesth Clin Pharmacol 2009 
      Fifty adult patients belonging to ASA physical status I or II, scheduled for 
laparoscopic Cholecystectomy were selected and randomly allocated to two 
groups A & B. Group A (clonidine) received Tab. clonidine 150μg orally and 
Group B (Control) received Tab. vitamin B complex orally as premedication 
60-90 minutes before scheduled laparoscopy. Heart rate and mean blood 
pressure were recorded prior to intubation, 15 min after endotracheal intubation, 
at skin incision, 15 min and 30 min after creation of pneumoperitoneum and 15 
min after release of pneumoperitoneum. 
Conclusion: Premedication with oral clonidine 150 µg provides stable 
hemodynamics in patients undergoing laparoscopic cholecystectomy. 
 
2. Mrinmoy et al -Indian Journal of Anaesthesia 2007 
      Sixty adult patients of ASA physical status I & II, scheduled for elective 
laparoscopic cholecystectomy were recruited for a prospective randomized, 
double-blinded comparative study. They were randomly allocated to one of the 
two groups to receive either oral clonidine 150 µg (Group C) or ranitidine 150 
  
mg (Group P), 90 minute before induction of anaesthesia. Significant rise in 
heart rate was observed following pneumoperitoneum in Group P as compared 
to Group C. Similarly, rise in systolic arterial pressure , diastolic arterial 
pressure and mean arterial pressure was more in Group P following 
pneumoperitoneum. Incidence of postoperative nausea-vomiting and shivering 
was also less in Group C. 
To conclude, clonidine premedication provides perioperative haemodynamic 
stability, hence it can be recommended as a routine premedication for 
laparoscopic procedure. 
 
3.Masayoshi Uchida et al -  Can J Anesth  2004  
Studied 60 adult patients (ASA physical  status I) were randomly assigned to 
one of two groups. Thirty patients received famotidine 20 mg (control group) 
orally 90 min before the induction of anesthesia, whereas the remaining 30 
patients received clonidine 5 μg/kg and famotidine 20 mg (clonidine group). 
General anesthesia was induced with iv propofol 2 mg/kg , and tracheal 
intubation was facilitated with iv vecuronium 0.2 mg/kg. In 15 patients in each 
group, anesthesia was maintained with isoflurane 1% (end-tidal) in oxygen, and 
in the other 15 patients with iv propofol 100 μg/kg/min during ventilation with 
oxygen. MAP, CI and HR responses to hypercapnia in the clonidine-propofol 
subgroup were significantly attenuated compared with those in the other three 
subgroups. Plasma norepinephrine concentrations (but not epinephrine 
  
concentration) were significantly lower in clonidine-propofol patient. The 
cardiovascular effects of hypercapnia are suppressed in patients given clonidine 
prior to propofol anesthesia, perhaps due to the profound suppression of 
sympathetic nervous system activity. The hemodynamic response to 
hypercapnia depends on the level and extent of any sympathetic blockade. The 
interaction between the basal anaesthetic agent and clonidine (given as a 
premedicant) can apparently modify the hemodynamic  response to 
hypercapnia to a significant extent. 
 
4. Yu  et al - Acta Anaesthesiol Scand 2003 
      Thirty-two patients scheduled for elective laparoscopic cholecystectomy 
were recruited for a prospective, randomized, double-blinded comparative 
study. They were allotted randomly to two groups: placebo or clonidine. 
Patients in the placebo group (n = 16) were premedicated with oral antacid, 
while those in the clonidine group (n = 16) were premedicated with oral 
clonidine 150 µg before anesthesia. Analysis of heart rate variability was used 
to quantify the control of heart rate at baseline, and during the 
pneumoperitoneum and recovery periods. Time of the first request for 
postoperative analgesic and cumulative analgesic requirements in 24 h were 
recorded. Data are expressed as mean ± SD. 
  
Conclusion: Clonidine preserves heart rate control in pneumoperitoneum and 
recovery periods. Oral clonidine premedication also reduces the requirement for 
postoperative analgesia. 
 
5. Laisalmi et al -  Surg Endosc 2001 
     The effects of clonidine 4.5 mg/kg or saline on hemodynamics, 
neuroendocrine response, and renal parameters were compared in 30 healthy 
patients undergoing laparoscopic cholecystectomy. Heart rate, arterial blood 
pressures, and plasma renin activity were lower during and after 
pneumoperitoneum in patients with clonidine. There were no differences in 
urine output, urine oxygen tension (reflecting medullary perfusion), or 
antidiuretic hormone between the groups. N-acetyl-b-D-glucosaminidase, a 
marker of proximal tubular damage, was minimally elevated after clonidine. 
CONCLUSIONS: Clonidine enabled stable hemodynamics and prevented 
activation of RAAS seen as unchanged plasma renin activity. Clonidine may be 
beneficial during laparoscopy in patients with hypertension, cardiovascular, 
and/or renal diseases. 
 
6.Sung et al- Acta Anaesthesiol Sin. 2000 
   One hundred and ten patients, scheduled for elective laparoscopic 
cholecystectomy, were recruited for the prospective, randomized, single-blind, 
comparative study. They were randomly allotted to either of the placebo or 
  
clonidine group. Patients of the placebo group (n = 65) were premedicated with 
oral antacid (alugel hydroxide 300 mg), while those in the clonidine group (n = 
45) were premedicated with oral clonidine 150 micrograms prior to anesthesia. 
The premedication was given 60 to 90 min before the anticipated time of 
induction of anesthesia. Normocapnia was maintained throughout the 
perioperative period. Mass spectrometer was used to assess the inspired and 
expiratory concentrations of isoflurane, the anaesthetic used for maintenance of 
anaesthesia. Postoperative pain intensity, sedation scores, adverse events, time 
to the first dose of postoperative analgesic and cumulative analgesic 
requirement in 24 hours were recorded.  
CONCLUSIONS: Oral clonidine premedication helped to provide perioperative 
hemodynamic stability, spared the use of isoflurane and reduced the 
requirement of postoperative analgesia so as to smoother the way to recovery in 
patients undergoing 
 
6.Malek et al 1999 
confirmed in their work involving 21 patients the incidence of these effects and 
tried to suppress them by premedication with clonidine (CATAPRESAN, 
Boehringer). 21 patients were given 0.15 mg clonidine in an infusion 15 
minutes before operation and 21patients 0.15 mg clonidine by the i.m. route 60-
90 min. before operation. Standard anaesthesia was administered. A highly 
significant drop in the incidence of hypertension was recorded during operation 
  
for systolic pressure (p < 0.001) after both ways of administration, as well as of 
diastolic pressure (p < 0.01 for intravenous and p < 0.05 for intramuscular 
premedication). Premedication with intravenous clonidine can be recommended 
as a routine procedure before laparoscopic cholecystectomies 
 
7.Koivusalo and colleagues- Acta Anaesthiol Scand 1998            
Found that high-dose esmolol (200 µg /kg/ min) with alfentanil effectively 
blunted the sympathetic response to the painful stimulus of pneumoperitoneum 
in ASA I and II patients, whereas alfentanil alone was ineffective. The 
difference in esmolol dose needed to effectively blunt sympathetic responses to 
intraoperative manipulation may be due to different sensitivity to ß-blockers 
between ethnic groups with hypertension in these studies. 
 
9. Korpinen R - Acta Anaesthesiol Scand. 1997 
conducted a double-blind study in 40 patients of ASA grade I and II. Patients 
were allocated to receive either Esmolol or saline under Thiopentone-
Alfentanil-Isoflurane Suxamethonium anaesthesia. Esmolol in a dose of 1 
mg/kg + 200 µg/kg/min was given. This study showed that in Esmolol group, 
neither heart rate nor the QTc interval of ECG increased when compared to 
baseline values. On the basis of this study it is concluded that Esmolol bolus 
followed by infusion is a useful treatment in circumstances where an increase in 
  
heart rate, prolongation of QTc interval and cardiac arrhythmias are to be 
avoided. 
 
10. A Vucevic (1992) 
 Double-blind randomized controlled study was carried in 30 ASA grade I and 
II patients to manage the cardiovascular stress response to tracheal intubation 
using Esmolol as a continuous infusion. Patients in study group received 
Esmolol 500 µg/kg/min for 2 minutes as a loading dose and thereafter a 
maintenance infusion of 100 µg/kg/min. Heart rate, systolic blood pressure, and 
rate pressure product were monitored and recorded at baseline, before induction 
and maximum after intubation. The analysis of this study showed that maximum 
rate pressure product recorded in association with tracheal intubation was 
significantly reduced in patients who received Esmolol infusion. 
 
11. Donald Oxorn et al (1990) 
A clinical study was conducted by 9 in 48 patients undergoing hysterectomy. 
Patients were randomly assigned to receive a single IV bolus dose Esmolol 100 
mg or 200 mg or a placebo. Heart rate, systolic blood pressure and diastolic 
blood pressure were monitored throughout the study. They concluded that 
single bolus dose of 100 mg or 200 mg Esmolol was effective in ameliorating 
the tachycardic response to LTI. Esmolol also decreased the incidence of post-
  
intubation ventricular arrhythmias. No side effects attributable to Esmolol were 
seen. 
 
12. Shane Sheppard et al (1990) 
 Conducted a study using bolus dose of Esmolol in 45 patients of ASA grade I 
and II undergoing various non-cardiac surgical procedures. Subjects were 
allocated randomly to receive Esmolol 100 mg or 200 mg IV or placebo. 
Changes in heart rate, systolic blood pressure were monitored at baseline, 1 
minute,3 minute and 5 minute respectively. They concluded that adequate 
haemodynamic control was obtained following administration of 200 mg 
Esmolol bolus. 
 
13. Aho et al - Anaesthesiology 1990 
 Ninety women undergoing gynecologic laparoscopy were randomly given 
clonidine 3 or 4.5 micrograms/kg or saline intramuscularly 45-60 min prior to 
induction of anaesthesia. Anaesthesia was induced with thiopental 3.5 mg/kg 
and maintained with 0.3% end-tidal isoflurane in nitrous oxide and oxygen. The 
laparoscopy did not begin sooner than 20 min after tracheal intubation. Arterial 
blood pressure and heart rate were monitored with an automatic oscillometer. 
When compared with the baseline values, clonidine 4.5 micrograms/kg 
significantly (P less than 0.001) decreased the mean arterial pressure (MAP) 
measured before induction of anaesthesia. In all three groups, blood pressure 
  
and heart rate increased after tracheal intubation and after beginning of 
laparoscopy (P less than 0.001), but the increments were significantly greater in 
the control group than in the study groups. During anaesthesia alone without 
surgical stimulation, and again in the recovery room, MAP and heart rate were 
lower in the study groups than in the control group. Plasma beta-endorphin 
immunoreactivity (ir beta-E) was measured for ten control-group women and 
ten women receiving clonidine 4.5 micrograms/kg before premedication, before 
and after induction of anaesthesia, during laparoscopy, and 1 h after the 
procedure. The plasma ir beta-E increased significantly after the beginning of 
laparoscopy in both the control group and those given clonidine, but the 
increase was significantly less (P less than 0.05) in the women premedicated 
with clonidine. The blunting effect of clonidine on hemodynamics and plasma 
beta endorphin may reflect a deeper level of anaesthesia in those women 
receiving clonidine as preanaesthetic medication or can be explained by an 
interaction of clonidine with endogenous opiates. The authors conclude that 
intramuscularly administered clonidine premedication effectively prevents the 
maximal hemodynamic responses to tracheal intubation and to gynecologic 
laparoscopy.  
 
14. Joris et al - Br J Anaesth 1995 
Used very high dose of clonidine (8 µg/kg) for reducing the level of 
catecholamine and vasopressin following pneumoperitoneum conducted two 
  
studies, each including 20 healthy patients scheduled for elective laparoscopic 
cholecystectomy. In the first study serial measurements of hemodynamics 
(thermodilution technique) were done during laparoscopy and after 
exsufflation. Plasma concentrations of cortisol, catecholamines, 
vasopressin, renin, endothelin and prostaglandins were measured at the 
same time points. In the second study patients were randomly allocated to 
receive 8µg/kg clonidine infused over 1 h or placebo before pneumoperitoneum. 
Hemodynamics and plasma levels of cortisol, catecholamines and vasopressin 
were measured during pneumoperitoneum and after exsufflation. Clonidine 
significantly reduced mean arterial pressure, heart rate and the increase in 
systemic vascular resistance. Clonidine also significantly reduced catecholamine 
concentrations but did not alter vasopressin and cortisol plasma concentrations. 
Conclusion- Vasopressin and catecholamines probably mediate the increase in 
systemic vascular resistance observed during pneumoperitoneum. Clonidine 
before pneumoperitoneum reduces catecholamine release and attenuates 
hemodynamic changes during laparoscopy. 
15. Lee and Lee- Korean J Anesthesiology 2010 
Studied 60 patients who underwent a laparoscopic appendectomy under total 
intravenous anesthesia using propofol and remifentanil and compared a control 
group with another group that received continuously injected esmolol during 
anaesthesia. Postoperative 30 minute visual analog scale (VAS) scores and 
  
diclofenac sodium use for postoperative pain control during the first 24 hours 
decreased significantly in the esmolol group. Also, Lee and Lee [6] adjusted the 
infusion rate of remifentanil to target the bispectral index (BIS) to 40-60, 
compared to the control group, and the total amount of remifentanil 
administered during approximately 57 minutes of anesthesia was significantly 
lower in the esmolol group. The authors attributed the decrease in postoperative 
pain with esmolol to its intrinsic analgesic effect, a decrease in hepatic 
metabolism of opioids by β-blockers to extend the analgesic effect, and a 
reduction in opioid tolerance. 
 
16. T. Ozturk et al  - Br J Anaesth 2008 
Fourty consecutive ASA class II patients with controlled hypertension about to 
undergo laparoscopic cholecystectomy were randomized into two groups: an 
esmolol group (Group E) was given a 1 mg/ kg bolus of esmolol and a placebo 
group (Group P) was given an identical volume of Ringer’s lactate. The rate of 
esmolol infusion was adjusted to keep the heart rate between 65 and 75 beats 
/min and was 5–10 µg/ kg /min throughout the procedure. After operation, 
patients reported their nausea using a four-point scale. 
Conclusions.  Esmolol had an opioid-sparing effect in the intraoperative and 
immediate postoperative period in hypertensive patients undergoing 
laparoscopy. When combined with alfentanil, it was more effective than placebo 
in decreasing early PONV. 
  
 
17. Vincent Collard et al - Anesth Analg 2007 
Ninety patients (consisting of three groups) were enrolled in this prospective, 
randomized, and observer-blinded study. The control group (n _ 30) received 
intermittent doses of fentanyl, the esmolol group (n _ 30) received a continuous 
infusion of esmolol (5–15 µg /kg/min) and no supplemental opioids during 
surgery, and the remifentanil group (n _ 30) received a continuous infusion of 
remifentanil (0.1– 0.5 µg /kg/min). General anaesthesia was standardized, and 
adjuvant medications included acetaminophen, ketorolac, local anesthetics in 
the skin incisions, dexamethasone, and droperidol. Postoperative analgesia 
included fentanyl. 
CONCLUSIONS: Intraoperative IV infusion of esmolol contributes to a 
significant decrease in postoperative administration of fentanyl and ondansetron 
and facilitates earlier discharge. 
 
18. White et al. - Anesth Analg 2003  
Using gynecologic surgical model, administered 1.5µg/kg of fentanyl at 
induction, followed by an infusion of esmolol, and found that this group 
required less postoperative opioids. 
 
 
 
  
19. Coloma and colleagues - Anesth Analg 2001 
 Found that esmolol decreased the incidence of PONV more than remifentanil 
after desflurane-based fasttrack anaesthesia for outpatient gynaecologic 
laparoscopic surgery. perioperative esmolol is an alternative to remifentanil for 
maintaining stable intraoperative hemodynamics. Although intravenously 
administered esmolol has peripheral analgesic and cardiovascular properties, it 
is also thought to be involved in pain modulation. 
 
                                                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                   METHODOLOGY 
 
SOURCES OF DATA 
Data was collected from 90 ASA I and II patients scheduled for laparoscopic 
appendicectomy aged between 15-50 years at Madurai Medical College, Govt. 
Rajai Hospital, Madurai. Both study groups and control were selected from 
these patients. The study was conducted over a period of two years, August 
2009 to August 2010. 
 
INCLUSION CRITERIA 
• ASA 1and ASA 2 patients. 
• 15-50 age group. 
 
EXCLUSION CRITERIA 
• current treatment with a ß-blocker or calcium channel blocker 
• chronic use of opioid analgesics 
• history of asthma or reactive airway  disease, diabetes mellitus,  
• allergy to any of the medications used in the study 
• obesity or cachexia beyond the ideal body weight by at least 50% 
• Patients with history of hypertension, ischaemic heart disease, aortic 
stenosis, left ventricular failure and atrioventricular conduction block 
  
• Patients concomitantly taking clonidine, methyl dopa, beta blocking 
drugs, benzodiazepines and MAO inhibitors were also excluded from the 
study. 
• severe haemorrhage during operation or conversion to open 
appendicectomy 
• Patients who have taken antiemetic drugs within 24 hours before surgery. 
• Patients with history of neurological or renal diseases. 
 
METHODS 
The study was a prospective, randomized, double blinded one. The 
randomization was done using closed envelope technique.  
 
Preanaesthetic evaluation: 
1. History 
2. Clinical examination 
 3. Relevant investigations – haemoglobin, urine  analysis 
4. Informed consent from patients 
 
Preanaesthetic medication was given with tab.ranitidine 150 mg and 
tab.diazepam 10 mg, the night before and inj.midazolam 0.03mg/kg and 
  
inj.glycopyrrolate 0.2 mg i.m 45 min before surgery. After shifting the patient to 
the operation table SpO2, NIBP, ECG monitors were attached. The baseline 
values were recorded. IV access was established. Patients were randomly 
allocated into three groups. 
1) Group E – Those who receive Esmolol  (0.5 mg/kg bolus 5min before 
induction followed by continuous infusion of 100µ/kg/min through out the 
surgical procedure) 
2) Group C - Those who receive Clonidine  (3µ/kg in 100 ml saline as infusion 
15 min before induction) 
3) Group D - Those who received placebo (100ml normal saline) 
 
The drugs were given by an anaesthetist who is not involved in the study, for 
making the study double blinded.  
Anaesthesia was induced with intravenous administration of Propofol 2mg/kg 
and Fentanyl 2 mcg/kg and succinylcholine chloride2 mg/kg for muscle 
relaxation. Proper size cuffed oral endotracheal tube was inserted. Anaesthesia 
was maintained with NitrousOxide 67%, Oxygen 33% and intermittent doses of 
inj.atracurium and inj.fentanyl. Ventilation was controlled mechanically and 
was adjusted to keep ETCO2 between 30 and 35 mm of Hg. The intra 
abdominal CO2 pressure was kept between 13-16 mm of Hg. A nasogastric tube 
was inserted and suction applied to empty the stomach after intubation and also 
before extubation. 
  
 
 Haemodynamic instability is defined as heart rate <60 beats min or a MABP 
<75 mm Hg and was treated accordingly. Systemic arterial pressure including 
the systolic, diastolic and mean arterial pressure, heart rate, SpO2 were recorded 
every 15 min, including :  
(1) prior to induction  
(2) three minutes after endotracheal intubation 
(3) before pneumoperitoneum  
(4) fifteen minutes after pneumoperitoneum  
(5) thirty minutes after pneumoperitoneum  
(6) ten minutes after release of CO2 and  
(7) ten minutes after extubation.  
 
Reversal of muscle relaxation was done with inj.lycopyrolate 0.01 mg/kg body 
weight and inj.neostigmine 0.05 mg /kg and patient was extubated. 
Postoperative analgesia was provided by im inj.tramadol 50 mg as required. The 
total number of doses of analgesic required for 12 hours was monitored. 
Postoperatively all episodes of PONV experienced by the patient during the first 
24 hours after anaesthesia, was recorded by direct questioning. These were 
assessed by a nausea and vomiting score. Rescue Antiemetic (Metoclopramide 
10mg) was used if patient had nausea or vomiting and the number of doses 
  
required was monitored. Post operative sedation of the patient was monitored 
for 12 hours using the ramsay sedation score. 
 
NAUSEA AND VOMITING SCORE 
No nausea - 0 No vomiting - 0 
Mild nausea -1 Mild vomiting - 1 
Moderate nausea - 2 Moderate vomiting - 2 
Severe nausea - 3 Severe vomiting - 3 
 
RAMSAY SEDATION SCORE:  
LEVELS 1 -3 patient awake 
      LEVEL 1-anxious and agitated or restless or both 
      LEVEL 2-cooperative and oriented  
      LEVEL 3-responds to commands only 
LEVEL 4-6 patient asleep, responds to light glabellar tap or     loud auditory 
stimulus  
      LEVEL 4 –Brisk response 
      LEVEL 5 – Sluggish response 
      LEVEL 6 –No response 
 
Statistical Methods 
  
Information collected regarding all the selected cases were recorded in a Master 
Chart. Data analysis was done with the help of computer using Epidemiological 
Information Package (EPI 2008).  
Using this software range, frequencies, percentages, means, standard deviations, 
chi square and   'p' values were calculated. Kruskul Wallis chi-square test was 
used to test the significance of difference between quantitative variables. A 'p' 
value less than 0.05 is taken to denote significant relationship. 
                                    
 
 
 
 
 
 
              
                                                           
                                                                 
 
 
 
  
                                                  RESULTS 
The three groups were comparable in patient characteristics like age, sex and 
duration of surgery  
 
TABLE - 1 
AGE DISTRIBUTION 
 
AGE  in yrs GROUP E GROUP C GROUP D 
RANGE 15 – 55 18 – 45 16 – 45 
MEAN 27.8 27.3 29.1 
S.D 8.8 6.6 8.2 
 P 0.6021 – not significant 
 
Table -1 shows that the three groups were comparable in the distribution of age. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
                      FIGURE-1 AGE DISTRIBUTION 
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TABLE - 2 
 
SEX DISTRIBUTION 
 
 
Table - 2 shows that three groups were comparable in the distribution of sex. 
 
 
 
 
 
 
 
 
 
SEX GROUP E GROUOP C GROUP D 
NO % NO % NO % 
MALE 9 30 11 36.7 11 36.7 
FEMALE 21 70 19 63.3 19 63.3 
TOTAL 30 100 30 100 30 100 
p  - group E &C 0.7842 – not significant 
p – group E &D  0.7842 – not significant 
p – group C & D 1.0 – not significant 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                      FIGURE-2 SEX DISTRIBUTION 
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TABLE -3 
HEART RATE AT DIFFERENT TIME INTERVALS 
 
HR at 
min 
GROUP -E GROUP- C GROUP- D P 
Mean S.D Mean S.D Mean S.D 
PRE-I 86.8 8.0 88.4 10.2 85.9 12 0.597 
Not significant 
1 75.1 10.4 85.7 10.8 86.9 11.4 0.0001 Significant 
5 77.0 8.6 84.3 10.6 91.1 10.3 0.0001 
Significant 
15 77.9 10.5 83.6 10.3 92.0 9.2 0.0001 
Significant 
30 78.5 10.9 84.6 9.7 91.1 8.6 0.0001 
Significant 
45 79.6 12.9 84.3 10.5 92.7 9.3 0.0001 
Significant 
60 82.6 10.1 85.4 7.0 93.9 8.5 0.0002 
Significant 
75 84 11.6 91.3 10.1 92.5 9.2 0.059 
Not significant 
90 88.5 13.0 89.7 10.9 84.8 4.1 0.5845 
Not significant 
 
 
Table-3 shows a significant difference in the heart rate between the esmolol and 
clonidine group as compared with the control group at 1min , 5 min, 15 min ,30 
min 45 min and 60 min after intubation. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE-3 HEART RATE AT VARIOUS TIME INTERVALS 
 
Figure 3 shows the difference in the heart rate during the inta operative period 
between the three groups. The (Esmolol) Group –E has a lower heart rate as 
compared to the (clonidine) Group- C and the Control Group - D 
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TABLE- 4  
PERCENTAGE CHANGE IN HEART RATE FROM BASE LINE (PI) AT 
DIFFERENT TIME INTERVAL 
 
Table 4 -  shows a significant difference in the percentage decrease of heart rate 
from base line value in Esmolol group-E and Clonidine group – C as compared 
to control. 
 
 
%change 
In HR from 
base line 
rate- PI 
GROUP –E GROUP- C GROUP- D P 
Mean S.D Mean S.D Mean S.D 
1 13.6 7.2 2.7 9.9 -1.4 4.5 0.0001 
Significant 
5 11.2 6.6 4.0 12.6 -6.5 6.7 0.0001 
Significant 
15 10.2 9.6 4.7 12.6 -7.9 8.5 0.0001 
Significant 
30 9.4 10.7 3.5 12.0 -6.9 9.8 0.0001 
significant 
45 8.3 12.7 3.3 13.3 -8.8 10.8 0.0001 
Significant 
60 6.5 10.5 3.4 10.3 -9.7 10.5 0.0001 
Significant 
75 5.9 10.5 -0.9 12.3 -8.2 8.8 0.0107 
Significant 
90 11.2 5.3 -6.4 12.6 -11.7 9.0 0.0273 
Significant 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4 - PERCENTAGE OF CHANGES IN HEART RATE AT VARIOUS 
TIME INTERVALS 
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TABLE-5 
SYSTOLIC BLOOD PRESSURE AT VARIOUS TIME INTERVAL 
 
 
Table 5 - shows that there is a significant difference in the systolic blood 
pressure between the study groups and the control groups throughout the intra 
operative period. 
 
Systolic 
BP at min 
GROUP –E GROUP- C GROUP- D P 
Mean S.D Mean S.D Mean S.D 
PRE-I 123.9 9.9 123.4 12.1 126.7 14.5 0.2355 
Not significant 
1 108 13.2 117 12.8 127.3 13.4 0.0001 
Significant 
5 107.5 21.2 117.3 13.4 128.4 13.9 0.0001 
Significant 
15 114.6 11.3 117.6 12.5 133.5 10.5 0.0001 
Significant 
30 116.9 12.5 118.2 10.5 134.5 8.0 0.0001 
Significant 
45 118.2 13.0 119.5 9.3 135.4 8.5 0.0001 
Significant 
60 120.5 12.7 121.2 5.9 138 6.9 0.0001 
Significant 
75 119.9 10.9 123 4.6 138.9 6.7 0.0001 
Significant 
90 125.0 4.2 121.5 5.0 136.9 5.1 0.0054 
Significant 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5 - SYSTOLIC B.P. AT VARIOUS TIME INTERVALS 
 
Figure 5 shows that Esmolol Group- E has significantly lower systolic blood 
pressure as compared to Clonidine Gruop-C and Control Group-D throughout 
the intra operative period. 
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TABLE – 6 
 
PERCENTAGE CHANGES IN SYSTOLIC BLOOD PRESSURE FROM 
BASE LINE (PI)  AT VARIOUS INTERVALS 
 
Table 6 - shows that there is a significant difference in the percentage of 
decrease in systolic blood pressure from the (pre induction) baseline value in 
Esmolol and Clonidine group as compared to control group. 
 
 
% change 
in SBP 
from Pre-I 
at min 
GROUP -E GROUP- C GROUP- D P 
Mean S.D Mean S.D Mean S.D 
1 12.9 6.7 4.9 8.5 -0.8 6.5 0.0001 
Significant 
5 12.7 16.4 4.6 10.5 -1.7 7.3 0.0001 
Significant 
15 7.2 8.9 4.4 8.7 -6 6.4 0.0001 
Significant 
30 5.4 9.8 3.8 8.0 -7 8.1 0.0001 
Significant 
45 4.3 10.2 2.6 8.9 -7.8 9.2 0.0001 
Significant 
60 4.2 8.4 1.7 7.5 -5.2 7.0 0.0003 
Significant 
75 3.2 8.1 1.2 6.2 -6.5 9.1 0.0028 
Significant 
90 5.6 4.3 4.0 6.0 -3.1 9.2 0.0942 
Not significant 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6 – PERCENTAGE CHANGE IN SYSTOLIC BP AT VARIOUS 
TIME INTERVALS 
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TABLE -7 
DIASTOLIC BLOOD PRESSURE AT VARIOUS TIME INTERVALS 
 
Table 7 -  shows a significant difference in the diastolic blood pressure between 
the study groups and the control groups during the intra operative period 
 
 
 
Diastlic 
BP at 
min 
GROUP -E GROUP- C GROUP- D P 
Mean S.D Mean S.D Mean S.D 
PRE-I 80.2 6.3 80.2 7.4 80.3 6.7 0.9338 
Not significant 
1 69.9 8.5 75.6 8.3 81.1 5.2 0.0001 
Significant 
5 74.7 7.2 77.6 9.3 82.4 5.5 0.0001 
Significant 
15 75.0 7.2 77.9 7.4 85.6 5.2 0.0001 
Significant 
30 75.7 7.1 78.0 8.3 84.9 4.4 0.0001 
Significant 
45 76.8 7.1 79.9 5.7 85.7 4.5 0.0001 
Significant 
60 79 7.5 79.8 3.0 85.7 4.2 0.0001 
Significant 
75 79.5 7.8 82.2 2.2 86.7 4.0 0.0034 
Significant 
90 81.0 2.0 84.9 3.0 83.5 4.7 0.1523 
Not significant 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7 - DIASTOLIC B.P.  AT VARIOUS TIME INTERVALS 
  
Figure 7 shows that there is a significant difference in the diastolic blood 
pressure , with more decrease in the diastolic BP in the Esmolol Group-E as 
compared to the Clonidine Group- C and the control group- D. 
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TABLE- 8 
PERCENTAGE OF CHANGES IN DIASTOLIC BP FROM BASE LINE 
VALUE (PI) AT VARIOUS TIME INTERVALS 
 
Table 8 -  shows a significant difference in the percentage decrease in diastolic 
blood pressure from the base line (pre induction) value in Esmolol and 
Clonidine group as compared to control group. 
 
% 
change 
in DBP 
from PI  
at (min) 
GROUP -E GROUP- C GROUP- D P 
Mean S.D Mean S.D Mean S.D 
1 12.8 8.6 5.4 9.6 -1.2 5.0 0.0001 
Significant 
5 6.6 9.8 2.9 10.8 -2.9 7.0 0.0001 
Significant 
15 6.2 8.7 2.4 9.9 -6.9 6.6 0.0001 
Significant 
30 5.4 8.4 2.3 10.3 -6.1 6.8 0.0001 
Significant 
45 4.1 7.1 0.1 8.0 -6.6 5.8 0.0001 
Significant 
60 1.5 10.7 1.8 7.7 -4.5 5.4 0.0018 
Significant 
75 0.3 13.6 -1.4 5.7 -6.1 6.8 0.951 
Not significant 
90 1.5 6.8 1.5 6.8 -2.3 4.9 0.4138 
Not significant 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8 - PERCENTAGE OF CHANGES IN DIASTOLIC B.P.   
AT VARIOUS TIME INTERVALS 
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TABLE – 9 
 
FENTANYL REQUIREMENT 
 
FENTANYL  
REQUIREMENT 
GROUP – E GROUP - C GROUP – D 
Range 80-160 60-140 80 – 140 
Mean 109.7 110.3 116.7 
S.D 18.8 16.7 14.7 
P 0.1461 – Not significant 
 
 
 
Table 9 -  shows that there is no significant difference in the fentanyl 
requirement between the study group and the control group 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                        FIGURE 9 - FENTANYL REQUIREMENTS (MIC) 
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TABLE- 10 
 
ANTI-EMETIC DOSES 
 
ANTI-EMETIC 
DOSES 
GROUP – E GROUP - C GROUP - D 
Range 0 – 2 0- 2 0- 2 
Mean 0.77 0.97 1.07 
S.D 0.68 0.41 0.37 
P 0.0471 – significant 
 
 
Table 10  - shows that there is a significant difference in the requirement of anti 
emetics in the study groups and the control group 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                   FIGURE 10 - ANTI-EMETIC DOSES 
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TABLE-11 
 
SCORING OF NAUSEA AND VOMITING 
 
SCORING OF  
N & V 
GROUP – E GROUP - C GROUP- D 
Range 1- 3 1-3 1-3 
Mean 1.83 1.97 2.07 
S.D 0.71 0.41 0.37 
P 0.1836 – not significant 
 
Table 11 - shows that there is no significant difference in the grading of nausea 
and vomiting between the study groups and the control group 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              FIGURE 11 - SCORING OF NAUSEA AND VOMITING 
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TABLE – 12 
 
POST OPERATIVE ANALGESIC REQUIREMENT 
 
ANALGESIC  
REQUIREMENT 
GROUP – E GROUP- C GRUOP- D 
Range 1-3 1-3 2-3 
Mean 1.9 1.57 2.4 
S.D 0.55 0.63 0.5 
P 0.0001 – significant 
 
 
Table 12  - shows that there is a significant difference in the requirement of post 
operative analgesic between the study group and the control group 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 12 - POST OPERATIVE ANALGESIC REQUIREMENT 
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TABLE – 13 
 
SEDATION SCORE 
 
SEDATION 
SCORE AT 
GROUP – E GROUP- C GROUP - D P 
Mean S.D Mean S.D Mean S.D 
1 2.47 0.68 3.07 0.78 2.47 0.82 0.003 
significant
4 2.27 0.58 2.53 0.63 2.07 0.27 0.0016 
significant
6 2.1 0.4 2.1 0.4 2.03 0.18 0.7998 
not 
significant
 
 
 
Table 13  - shows that there is significant difference in the post operative 
sedation observed at  
1 hr and 4 hr between the study group and the control group. Significant 
difference is noted in the Clonidine Group – c 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 13 - POST OPERATIVE SEDATION 
 
Figure 13 shows that post operative sedation is more in the Clonidine group as 
compared with the Esmolol group and the control group, with significant 
difference noted in the1st hour and the 4th hour. 
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                                                     DISCUSSION 
 
Pneumoperitoneum during laparoscopy produces significant haemodynamic 
changes, which can be detrimental especially in elderly and haemodynamically 
compromised patients. Various techniques and pharmacological agents have 
been used to counteract these detrimental effects of pneumoperitoneum. This 
double blind prospective study was carried out in 90 adult patients, to evaluate 
the effect of Esmolol and clonidine in attenuating haemodynamic stress 
response associated with pneumoperitoneum. Esmolol is the first intravenous, 
short-acting, titratable β-blocker available for use in critical care and surgical 
settings. Esmolol is thought to be a “jack of all trades” among drugs used in 
anesthesia because it prevents and treats cardiovascular responses due to 
perioperative stimuli. 
 
Shane Sheppard et al in 1990 found that a bolus of 200mg Esmolol was 
adequate to produce hemodynamic stability in patients undergoing non cardiac 
surgical procedures. 
A vucevic in 1992 found that a loading dose of 500µg/kg/min for 2 min 
followed by a infusion of 100µg/kg/min reduced the intubation stress and 
maintained hemodynamic stability. 
Koivusalo et al in1998 found that high dose Esmolol (200µ/kg/min) with 
alfentanyl effectively blunted the hemodynamic response to pneumoperitonium. 
  
Korpinen in 1997 found that a bolus dose of 1mg/kg of Esmolol followed by a 
infusion 200µ/kg/min was useful in circumstances were a increase in heart rate 
and cardiac arrhythmias are avoided. 
 
In my study i used a bolus dose of 0.5 mg/kg of Esmolol 5 min before induction 
followed by a infusion of 100µ/kg/min through out the surgical procedure, it 
was observed that there was a significant reduction in the heart rate throughout 
the procedure, mean value of  78.5  ± 10.9 ,the mean range 75.1 ± 10.4 to 88.5 ± 
13.0 and the percentage reduction from the baseline value (pre induction) varied 
from a mean value of  13.6± 7.2 to  6.5± 10.5. Out of the 30 cases studied 3 
patients had bradycardia with heart rate less than 60 and required reduction in 
the dose of Esmolol infusion.  
 
There was also a significant difference in the systolic blood pressure in the 
Esmolol group as compared with the control throughout the procedure. The 
mean systolic blood pressure was 116.9 ± 12.5, and was kept in the range of 108 
±13.2 to 125 ± 4.2. The percentage reduction in the mean systolic BP observed 
was 5.4 ± 9.8, with a maximum reduction of 12.9 ± 6.7. 
There was also a significant difference in the diastolic blood pressure, with a 
mean BP of 75.7 ± 7.1.Mean ranging from 69.9 to 81.0. 
 
  
Ozturk et al had observed a opioid sparing effect with intra operative use of 
Esmolol, in my study i didnot observe any significant reduction in the intra 
operative fentanyl requirement. 
Ozturk et al (2008) and Coloma et al (2001) observed that Esmolol produced a 
reduction in the incidence of PONV in patients undergoing laproscopic 
surgeries. In my study i observed that there was a significant reduction  in the 
anti emetic requirement in the post operative period with a mean value of 0.77 , 
requirement ranging from 0 to 2, out of 30 patients studied 8 patients didnot 
require any anti emetic post operatively and only one patient required 2 doses of 
anti emetic. Maintaining a stable intraoperative blood pressure has been found 
to be an effective method of preventing PONV. 
 
Ozturk et al (2008), White et al (2001), Lee and lee (2010) found that intra 
operative use of Esmolol reduced the post operative analgesic or opioid 
requirement. In my study i observed a significant reduction in the post operative 
analgesic requirement in the patients who received intra operative Esmolol as 
compared with the control group. The mean requirement of 1.9 ± 0.55 and the 
control group requiring 2.4 ± 0.5. The hippocampus plays a role in nociception, 
a role predicated, on n-methyl-d-aspartate receptors. It then seems possible that 
the activation of hippocampal β-adrenergic receptors might play a role in 
nociceptive processes. If so, then blockade of these receptors should blunt the 
  
contribution of such β-adrenergic activation to the nociceptive process, thereby 
resulting in the attenuation of perceived pain intensity. 
 
Clonidine, an imidazoline derivative is a selective α2 adrenergic agonist. It is a 
potent antihypertensive drug. It produces a fall in the heart rate and blood 
pressure associated with decreased SVR and cardiac output. Clonidine inhibits 
the release of catecholamine and vasopressin and thus modulates the 
haemodynamic changes induced by pneumoperitoneum. 
 
Aho et al used 3 µg/kg and 4.5 µg/kg clonidine for suppression of 
haemodynamic response to pneumoperitoneum. Joris et al used very high dose 
of clonidine (8 µg/kg) for reducing the level of catecholamine and vasopressin 
following pneumoperitoneum. Malek et al used 150 µg of clonidine as i.v. 
infusion and intramuscularly while Sung et al and Yu et al used 150 µg of oral 
clonidine as premedication for maintenance of haemodynamic stability during 
pneumoperitoneum. 
 
In my study i used 3µ/kg of Clonidine as infusion 15 minutes before induction, 
there was a significant reduction in the heart rate throughout the intra operative 
period with a mean of 84.6 ± 9.7 , the range of intra operative heart rate was 
83.6 ±10.3 to 91.3 ± 10.1 there was  also a significant diference in the 
  
percentage fall from the pre induction value , with a mean percentage fall of 4.7 
± 12.6 . 
 
In my study there was a significant reduction in the systolic BP as compared 
with the control group, with mean systolic BP of 118.2 ± 10.5, the range of 
systolic BP observed was 117 ± 12.8 to 123.4 ± 12.1. There was also a 
significant percentage decrease in the systolic BP from the base line pre 
induction value as compared with the control, with a mean percentage decrease 
of 3.8 ± 8.0, with a maximum reduction of 4.9 ± 8.5. 
 
There was also a significant reduction in the diastolic BP as compared to the 
control with a mean of 78.0 ± 8.3, mean ranging from 75.6 ± 8.3 to 84.9 ± 3.0 . 
 
Clonidine interacts with the endogenous opiates beta-endorphins. The plasma 
level of beta-endorphins increases significantly after laproscopy. The blunting 
effect of clonidine on hemodynamics and plasma beta-endorphins may reflect a 
deeper level of anaesthesia in those receiving Clonidine. 
 
There was a reduction in the PONV in patients receiving Clonidine , with a 
mean anti emetic requirement of 0.97 ± 0.41 as compared to control with a 
mean value of 1.07 ± 0.37 ,out of 30 patients receiving Clonidine 10 patients 
did not require any antiemetic and 2 patients required two doses of antiemetic. 
  
 
Marimony et al (2007) found a decreased incedence of nausea and vomiting in 
patients receiving Clonidine. Clonidine increases gastrointestinal motility by 
decreasing sympathetic outflow and increasing parasympathetic outflow from 
the central nervous system. Although many workers have reported the 
antiemetic property of clonidine, the mechanism by which it acts warrants 
further investigation. 
 
Sung et al (2000) and Yu et al (2003) found that preoperative clonidine 
admistration reduced the post operative analgesic requirement. In my study 
there was a significant reduction in the post operative analgesic requirement in 
patients receiving clonidine. The mean analgesic dose requirement was 1.57 ± 
0.63 as compared to control group requiring 2.4 ± 0.5. 
 
In my study the post operative sedation score was observed for 6 hrs 
postoperatively and was found that clonidine group had a significantly high 
sedation score at 1 hr and 4 hr after the surgery. The mean sedation score at 1 hr 
was 3.07 ± 0.78 and at 4 hrs 2.53 ± 0.63. 
 
When compared with Esmolol and clonidine the intraoperative heart rate, 
systolic BP , Diastolic BP was better maintained with Esmolol Group Than with 
the clonidine Group. The mean heart rate maintained in the range of 75.1 ± 10.4 
  
to 88.5 ± 13.0 in the Esmolol group and 83.6 ±10.3 to 91.3 ± 10.1in the 
clonidine group. The mean systolic BP in Esmolol group was in the range of 
108 ±13.2 to 125 ± 4.2 and in clonidine group was in the range of 117 ± 12.8 to 
123.4 ± 12.1. It was found to be statistically significant. 
 
It was observed that post operative anti emetic requirement was significantly 
less in both Esmolol and Clonidine group. The requirement was more reduced 
in the Clonidine group as compared to Esmolol group, but the difference was 
not found to be statistically significant. 
 
Post operative analgesic requirement was also observed to be significantly 
lower in Esmolol and Clonidine group as compared to the control group. It was 
found to be more decreased in clonidine group than with Esmolol group, but the 
comparison found no significant statistical significance. 
 
Post operative sedation was more with clonidine group as compared to Esmolol 
and Control group. Esmolol group didnot have any significant increase in the 
post operative sedation as compared to control. 
 
No adverse effect was observed with the study group during the intra operative 
and post operative period. 
 
  
Some limitations with the design of the study. First, the anaesthesiologists who 
administered the anaesthetics might have been biased in the administration of 
the study drugs. Second, it is argued that the use of a BIS monitor would have 
ensured that the three groups had similar depth of anaesthesia.  
 
                                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                           
 
 
 
  
                                             SUMMARY 
 
Hemodynamic changes during laproscopic surgery is attributed to the stress 
response to pneumoperitonium. 
We studied ninety patients of both sexes coming to Madurai Medical College 
hospital for elective laparoscopic appendicectomy. The patients were 
randomized in to three groups to receive intravenously Esmolol 0.5µg/kg bolus 
followed by infusion of 100µ/kg/min or Clonidine 3μg/kg or placebo just before 
induction of anaesthesia. They were induced with propofol, succinyl choline, 
fentanyl was used as the intra operative analgesic. Anaesthesia was maintained 
with Nitrous oxide and Oxygen. Patients were observed for intra operative heart 
rate, systolic BP, diastolic BP. Hemodynamic stability was defines as heart rate 
in the range of 60 to 100 and blood pressure fall or rise not more than 15% from 
base line.  
Both Esmolol and Clonidine were effective in producing intra operative 
hemodynamic stability as compared to the control group by blunting the stress 
response to pneumoperitonium. No difference in adverse events was observed 
in the two groups. 
In addition , Esmolol and Clonidine were found to reduce the incidence of 
PONV and post operative analgesic requirement. 
                
     
  
                                                CONCLUSION 
 
Incidence of hemodynamic changes during laproscopic procedure is proven, and 
various methods of stress attenuation to pneumoperitonium is adviced. I decided 
to study the efficacy of Esmolol and Clonidine in maintaining hemodynamic 
stability in patients undergoing laproscopic appendicectomy. After 
premedication, patients were administered the study drugs intravenously prior to 
the induction and balanced general anaesthesia was administered. Patients were 
observed for intra operative hemodynamic stability which included heart rate, 
systolic and diastolic blood pressure. The study group was compared with a 
control group who received placebo. 
 
It was obsereved that a bolus dose of Esmolol of 0.5 mg/kg pre induction 
followed by an infusion of 100µ/kg/min during intra operative period or a pre 
induction dose of Clonidine 3µ/kg attenuated the hemodynamic stress produced 
by pneumoperitonium and produced intra operative hemodynamic stability. It 
was observed that Esmolol produced better hemodynamic stability than 
Clonidine.  
 
I conclude that both Esmolol and Clonidine produces hemodynamic stability for 
laproscopic appendicectomy, with more reduction in heart rate and blood 
pressure with Esmolol than Clonidine. 
  
 
        Additional observations were: 
 
• Both Esmolol and Clonidine reduced the incidence of post operative 
nausea and vomiting, more reduced with Esmolol. 
 
• Both Esmolol and Clonidine reduced the post operative analgesic 
requirement , more reduced with Clonidine. 
 
• Clonidine produced post operative sedation,were as Esmolol didnot have 
any sedative effect. 
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  PROFORMA-GROUP-   
NAME                                   AGE                   IP NOWT    
PRE MED- Glycopyrrolate 0.2mg  & Midazolam- 0.03 mg/kg 
PRE INDUCTION  - Study drug / Placebo 
INDUCTION-  Propofol 2mg/kg  Fentanyl 2 mics/kg   Suxa 2mg/kg 
MAINTANANCE-  Oxygen:NitrousOxide 2:3  , Atracurium, Fentanyl -20mics half hrly (if additional 
analgesic required suppl with 10 mics)  
(Group E -  100 mics/kg/min infusion) 
                                                                           MONITORING  PARAMETERS 
 PR SBP DBP 
Pre-induction/ 
Base line 
   
1 min    
5min    
15min    
30 min    
45 min    
60 min    
75min    
90 min    
105min    
120 min    
 
REVERSAL-  Neostigmine- 0.5mg/kg     
                   Glycopyrrolate- 0.01mg/kg 
TOTAL FENTANYL REQUIREMENT - 
PONV – 1hr-               4hr-                       6 hr- 
NO OF ANTI-EMETIC DOSES - 
NO OF ANALGESIC DOSES –
  
ESMOLOL‐SHEET 1 
 
 
SI NO  NAME  AG
E 
S
E
X 
HR‐
PI 
HR‐
1MI
N 
HR‐
5MI
N 
HR‐
15M
IN 
HR‐
30M
IN 
HR‐
45MI
N 
HR‐
60MI
N 
HR‐
75M
IN 
HR‐
90M
IN 
HR‐
105
MIN 
SBP‐
PI 
SBP‐
1MIN 
SBP‐
5MIN 
SBP‐
15MI
N 
SBP‐
30MIN 
SBP‐
45MI
N 
SBP‐
60MI
N 
SBP‐
75MI
N 
SBP‐
90MI
N 
SBP‐
105
MIN 
SBP‐
120MIN 
1  LAKSHMI  15  F  83  66  80  98 102 112 100 110 90  105 120 126 137  
2  PONPAITHI  40  F  90  86  92  96 98 98 100 112 112 89  100 116 114 120 130 130  
3  SELVARANI  15  F  100  100  90  82 78 78 124 120  84 86 84 90  
4  SUBHAMMAL  55  F  92  84  72  68 64 68 64 130 110  100 90 98 98 100  
5  BABU  19  M  90  96  98  102 100 100 100 120 100  100 110 110 110 110  
6  NAGAJYOTHI  34  F  78  72  70  72 74 72 74 70 100 90  92 100 105 100 105 100  
7  THAMILARASU  30  M  90  88  72  74 78 88 87 90 130 120  100 120 130 150 140 138  
8  PANDI  35  M  75  60  72  72 74 62 120 90  110 120 130 120  
9  GAYATHRI  25  F  82  68  72  78 74 70 72 120 100  110 110 100 100 100  
10  VIMALA  30  F  84  68  70  72 70 74 76 70 120 100  110 110 100 100 96 100  
11  CHELLAMMA  26  F  92  74  78  82 84 86 82 90 130 110  110 120 116 120 120 116  
12  PANDIAN  30  M  88  72  78  80 84 86 84 82 120 100  110 110 116 120 120 116  
13  SHARADHA  32  F  86  69  72  74 78 79 82 86 130 100  110 110 120 120 130 126  
14  HAJA MOHAMMED  35  M  94  74  78  84 84 86 88 88 90 140 100  110 110 110 126 130 120 126  
15  REKHA  21  F  78  62  68  70 72 72 78 120 110  118 118 120 118 120  
16  RAJU  18  M  80  72  74  70 73 78 120 110  112 118 120 120  
17  PICHAIAMMAL  40  F  87  74  72  70 68 72 74 80 120 108  110 116 112 116 118 120  
18  SHEELA  17  F  78  60  62  64 69 72 110 90  100 108 110 112  
19  VALLIAMMAI  28  F  98  80  90  88 82 88 90 94 88 130 120  124 120 124 124 126 120 120  
20  RAJAPANDI  31  M  92  80  82  80 82 84 82 130 120  124 126 126 130 120  
21  MARY  18  F  72  62  64  68 70 72 110 100  100 112 116 116  
22  JAYALAKSHMI  27  F  102  90  88  92 94 92 94 140 130  132 134 140 130 130  
23  FATHIMA  28  F  98  78  80  84 86 84 84 88 82 130 120  124 124 124 120 124 126 124  
24  BALAMURALI  34  M  94  80  82  80 84 90 88 140 130  13 126 130 134 140  
25  JAMUNA  31  F  84  78  79  80 82 84 88 84 84 130 130  130 132 134 130 132 134  
26  AZHAGI  26  F  84  76  78  70 72 68 72 70 120 100  110 112 112 110 110 116  
27  ANJALI  18  F  74  64  68  62 58 52 68 68 120 100  112 104 108 112 114 110  
28  BALASUBRAMANIAM  19  M  78  62  68  58 58 54 68 120 102  112 100 110 110 112  
29  PARAMESHWARI  31  F  88  78  80  82 82 84 88 140 126  128 130 132 134 140  
30  SHANMUGAPRIYA  26  F  93  80  82  84 82 84 82 88 80 88 130 124  126 126 130 120 124 126 130 130 130 
  
SI 
 
N
O 
NAME  AG
E 
SE
X 
DBP‐PI  DBP‐
1MIN 
DBP‐ 
5MIN 
DBP‐
15MIN 
DBP‐
30MI
N 
DBP‐
45MI
N 
DBP‐
60MI
N 
DBP‐
75MI
N 
DBP‐
90MI
N 
DBP‐
105MI
N 
FENTANYL 
REQUIREM
ENT(MIC) 
NO OF 
DOSES OF 
ANTI‐EMITIC 
SCORIN
G OF N 
&V 
POST OP 
ANALGESIC 
REQUIREMEN
T 
SEDATI
ON 
SCORE‐
1HR 
SEDATIO
N 
SCORE‐
4HR 
SEDATIO
N SCORE‐ 
6HR 
1  LAKSHMI  15  F  70  50  90 70 70 70 80 1 1 2 3 2 2 
2  PONPAITHI  40  F  74  56  60 66 77 70 90 90     120 NIL 1 2 3 2 2 
3  SELVARANI  15  F  84  80  68 64 64 60         80 1 2 2 2 2 2 
4  SUBHAMMAL  55  F  78  60  62 64 62 64 60 120 1 2 3 2 2 2 
5  BABU  19  M  80  70  70 70 70 80 80       100 NIL 1 2 2 2 2 
6  NAGAJYOTHI  34  F  70  60  60 60 60 64 68 70     80 1 2 2 4 3 2 
7  THAMILARASU  30  M  70  70  70 76 75 70 90 90     160 NIL 1 1 2 2 2 
8  PANDI  35  M  80  60  70 70 70 70 100 NIL 1 2 3 2 2 
9  GAYATHRI  25  F  70  60  70 66 66 70 70       120 1 2 2 2 3 2 
10  VIMALA  30  F  80  70  70 60 60 70 80 60     120 1 2 2 2 2 4 
11  CHELLAMMA  26  F  80  70  80 80 76 76 70 80 100 1 3 2 2 4 2 
12  PANDIAN  30  M  80  60  70 80 80 80 70 80     120 NIL 1 2 3 2 2 
13  SHARADHA  32  F  90  60  70 80 80 86 90 86     100 1 2 2 2 2 2 
14  HAJA MOHAMMED  35  M  90  70  80 70 80 86 80 70 90   120 1 2 2 2 2 2 
15  REKHA  21  F  70  64  70 72 74 74 74 100 2 3 1 2 2 2 
16  RAJU  18  M  80  70  80 80 80 80         90 NIL 1 3 2 2 2 
17  PICHAIAMMAL  40  F  80  80  80 80 80 80 80 82     140 1 2 2 4 3 2 
18  SHEELA  17  F  80  70  80 80 80 80 100 1 2 1 3 4 2 
19  VALLIAMMAI  28  F  90  80  80 80 80 82 80 80 80   120 1 2 2 2 2 2 
20  RAJAPANDI  31  M  90  80  80 80 84 80 80       100 1   1 3 2 2 
21  MARY  18  F  80  76  78 80 78 78         90 NIL 1 2 2 2 2 
22  JAYALAKSHMI  27  F  90  80  84 84 80 82 80 120 2 3 2 3 2 2 
23  FATHIMA  28  F  80  76  78 80 78 80 82 82 80   140 2 3 2 4 3 2 
24  BALAMURALI  34  M  80  74  78 80 80 82 80       120 1 2 2 2 2 2 
25  JAMUNA  31  F  80  80  80 82 84 82 83 80 120 NIL 1 2 2 2 3 
26  AZHAGI  26  F  80  72  76 78 78 80 78 78     100 1 2 1 2 2 2 
27  ANJALI  18  F  80  72  70 74 78 80 78 80     90 1 2 3 2 2 2 
28  BALASUBRAMANIA
M 
19  M  80  70  74 78 80 78 80       100 NIL 1 1 3 2 2 
29  PARAMESHWARI  31  F  90  80  80 82 84 90 90       120 2 3 2 2 2 2 
30  SHANMUGAPRIYA  26  F  80  78  82 84 82 80 82 84 84 80  120 1 2 2 2 2 2 
ESMOLOL‐SHEET 2 
  
SL  
NO 
NAME  AGE  SEX  HR‐PI  HR‐1 
MIN 
HR‐5
MIN 
HR‐
15 
MIN 
HR‐
30 
MIN 
HR‐
45 
MIN 
HR‐
60 
MIN 
HR‐
75 
MIN 
HR‐
90 
MIN 
HR‐
105 
MIN 
SBP‐PI  SBP‐
1 
MIN 
SBP‐
5 
MIN 
SBP‐15MIN SBP‐
30 
MIN 
SBP‐
45 
MIN 
SBP‐
60 
MIN 
SBP‐
75 
MIN 
SBP‐
90 
MIN 
SBP‐
105 
MIN 
SBP‐
120 
MIN 
1  KANNAN  41  M  100  70  60 58 62 64         160  140 140 140 130 136          
2  NAGARAJAN  23  M  90  94  84 80 82 86 86       120  90 90 100 110 110 120        
3  VELMURUGAN  25  M  96  82  84 86 82 84 86       124  90 90 92 106 110 110        
4  MOHAMMED  18  M  88  82  80 82 80 78 78 110  105 100 102 104 104 108  
5  KAVITHA  22  F  98  92  90 92 90 94         110  100 90 92 90 94          
6  KALAVANI  28  F  98  94  90 88 82 84 80       140  130 120 130 134 126 124        
7  ARUMUGAM  31  M  84  94  92 88 90 82 88 130  132 130 120 124 120 124  
8  INDRA  27  F  84  82  95 94 88 82 88 110  112 116 116 112 114 120  
9  VELUCHAMI  31  M  72  74  80 74 72 71         110  112 114 110 112 116          
10  HABEEBA  34  F  94  98  102 98 97 94 88 88     130  134 136 130 126 120 124 120      
11  SULTHANA  28  F  112  116  101 98 94 96 94 98 120  126 124 130 132 126 124 124  
12  INDRANI  26  F  102  104  101 98 94 92 88 94     120  126 128 130 132 134 130 120      
13  BANUMATHI  26  F  98  99  94 92 88 82         120  126 124 124 120 120          
14  KURUVAMMAL  34  F  80  82  84 80 82 84 86       110  114 116 120 120 124 120        
15  MANGALAM  30  F  72  82  84 80 76 78 80 82 82   120  124 126 130 128 126 130 130 124    
16  KALA   19  F  100  93  94 74 98           124  100 96 100 110            
17  MUTHU  18  M  73  80  63 63 79 93         105  100 126 96 100 125          
18  BAKYAM  33  F  92  74  74 82 84 84 86 82 82 140  120 126 130 126 124 126 124 124  
19  MEENAKSHI  21  F  82  84  88 92 90 88 84       120  110 114 116 114 120 120        
20  BARVEEN  22  F  72  76  78 80 80 82         110  112 114 114 118 112          
21  KASTHURI  20  F  78  76  82 84 80 80 84 120  112 115 118 118 116  
22  LAKSHMI  34  F  92  98  98 100 112 112 100 112 108 130  134 130 128 124 128 124 126 124  
23  KANAGAMMAL  45  F  92  84  80 78 79 80 82       140  130 132 124 126 120 120        
24  MUTHAIAH  24  M  90  92  88 94 98 110 102 98     120  116 105 124 126 128 126 128      
25  BARHATH NISHA  29  F  84  80  82 88 90 82 130  120 124 122 120 124  
26  CHELLAPPA  34  M  80  68  72 70 78 68 72       120  118 120 116 118 120 120 120      
27  PONUTHAI  28  F  84  80  78 84 80 78         140  124 126 124 120 124          
28  DINESH  18  M  78  80  82 78 76 74 82 84 82   118  112 108 114 102 100 112 114 114    
29  VIGNESHWARAN  25  M  90  82  80 78 80 84 80 84 130  124 120 124 126 124 120 124  
30  RAJATHI  26  F  98  78  68 74 76 78 80       120  116 118 112 118 120          
CLONIDINE‐ SHEET1 
  
L NO  NAME  AG
E 
S
E
X 
DB
P‐
PI 
DBP‐
1MI
N 
DBP‐
5MIN 
DBP‐
15MIN 
DBP‐
30MIN 
DBP‐
45MIN 
DBP‐
60MIN 
DBP‐
75MIN 
DBP‐
90MIN 
DBP‐
120
MIN 
FENTANYL 
REQUIREM
ENT(MIC) 
NO OF 
DOSES OF 
ANTI‐
EMITIC 
SCORIN
G OF N 
&V 
POST OP 
ANALGESIC 
REQUIREM
ENT 
SEDATI
ON 
SCORE‐
1HR 
SEDA
TION 
SCOR
E‐4HR 
SEDATION 
SCORE‐ 6HR 
1  KANNAN  41  M  10
0 
90  100  90 90 92 130 1 2 1 4 2 2 
2  NAGARAJAN  23  M  80  60  60  60 60 70 80       120 NIL 1 1 4 3 2 
3  VELMURUGAN  25  M  92  60  60  62 64 70 70       140 1 2 2 4 3 2 
4  MOHAMMED  18  M  70  70  68  68 70 72 74       100 NIL 2 2 3 2 2 
5  KAVITHA  22  F  70  60  60  64 62 64 100 1 2 2 3 2 2 
6  KALAVANI  28  F  90  90  90  84 86 88 84       120 NIL 2 1 2 2 2 
7  ARUMUGAM  31  M  90  82  84  86 90 86 84       120 NIL 2 2 3 2 2 
8  INDRA  27  F  80  78  80  82 82 82 80       120 1 2 1 2 2 2 
9  VELUCHAMI  31  M  70  70  72  76 76 78         120 NIL 1 2 3 2 2 
10  HABEEBA  34  F  80  80  82  82 84 86 82 86 120 1 2 2 4 3 2 
11  SULTHANA  28  F  80  82  82  80 82 80 80 80     100 2 3 2 4 3 2 
12  INDRANI  26  F  78  78  80  80 80 80 80 86     100 1 2 1 4 2 2 
13  BANUMATHI  26  F  70  78  80  80 78 82         100 NIL 2 1 3 3 2 
14  KURUVAMMAL  34  F  70  72  80  80 78 78 80       120 1 2 3 2 2 2 
15  MANGALAM  30  F  80  80  86  84 86 84 80 82 80 120 1 2 1 2 4 3 
16  KALA   19  F  76  60  56  66 64           60 1 2 1 2 3 2 
17  MUTHU  18  M  76  70  80  70 60 80         80 NIL 2 2 3 2 2 
18  BAKYAM  33  F  90  80  82  82 80 84 80 80 80   120 1 2 2 2 2 2 
19  MEENAKSHI  21  F  80  70  78  86 80 80 80       100 1 2 1 3 3 2 
20  BARVEEN  22  F  70  68  72  74 76 76 100 1 2 1 3 3 2 
21  KASTHURI  20  F  80  74  74  78 80 80         100 1 2 3 3 2 2 
22  LAKSHMI  34  F  80  82  84  82 84 82 80 82 84   120 NIL 2 2 4 2 2 
23  KANAGAMMAL  45  F  90  78  80  80 82 84 80       100 1 2 2 4 2 2 
24  MUTHAIAH  24  M  80  787  82  80 80 78 82 82     120 NIL 2 1 3 3 2 
25  BARHATH 
NISHA 
29  F  80  78  76  78 80 80 100 1 2 2 3 4 2 
26  CHELLAPPA  34  M  84  80  82  84 82 80 80 82     140 1 2 1 4 3 2 
27  PONUTHAI  28  F  80  78  82  80 82 80 120 2 3 1 4 3 2 
28  DINESH  18  M  80  78  80  82 80 78 80 82 80   100 NIL 2 2 3 3 4 
29  VIGNESHWARA
N 
25  M  80  76  78  78 80 82 80 80 120 NIL 1 1 2 2 2 
30  RAJATHI  26  F  80  80  78  80 82 80 80       100 1 2 1 2 2 2 
CLONIDINE‐ SHEET2 
  
SL 
 
NO 
NAME  AGE  S
E
X 
HR‐
PI 
HR‐
1MI
N 
HR‐
5MI
N 
HR‐
15M
IN 
HR‐
30M
IN 
HR‐
45M
IN 
HR‐
60MI
N 
HR‐
75M
IN 
HR‐
90MI
N 
HR‐
105MI
N 
SBP‐
PI 
SBP‐ 
1MI
N 
SBP‐
5MI
N 
SBP‐
15MI
N 
SBP‐
30MI
N 
SBP‐
45MI
N 
SBP‐
60MI
N 
SBP‐
75MI
N 
SBP‐
90MI
N 
SBP‐
105M
IN 
SBP‐
120M
IN 
1  KUPPUSAMY  30  M  70  76  72  70  66  68  78  74  70     140  120  100  130  140  146  146  150  130       
2  SUBBIAH  34  M  88  84  90  94  86  82  100  102  100     130  130  140  140  130  140  140  130  130       
3  MANIARASU  45  M  64  62  66  72  74  64  68  78  82     140  130  140  150  150  140  140  140  140       
4  SREENIVASAN  32  M  78  82  89  90  94  92  94           140  136  138  140  146  144  140  142          
5  BALAKRISHNAN  28  M  92  94  96  98  100  94  98  98        120  120  130  130  134  150  136  134          
6  RAMU  34  M  96  94  92  90  94  98  92  90        140  146  140  150  140  140  140  150  150       
7  VELLAISAMY  25  M  66  68  72  78  78  80              130  136  138  138  136  134                
8  ARJUN  18  M  98  100  102  98  96  98  100  98  98     110  112  120  128  130  132  136  138  136       
9  MARUDUPANDI  34  M  78  74  78  80  90  86  84  90  96     140  140  136  140  136  138  140  136  138       
10  KARUPPIAH  24  M  82  88  90  86  80  90  92  88        130  120  130  130  140  130  130  134          
11  LOGESHWARI  17  F  110  100  104  98  108  104  100  106        100  90  110  120  126  130  124  128          
12  KASIAMMAL  21  F  78  80  92  94  88  96              120  128  124  130  132  130                
13  SELVI  18  F  96  98  100  104  94  90  94  96        140  140  136  138  140  142  144  142          
14  PREMA  21  F  88  90  92  96  90  96              120  124  120  128  130  134                
15  JYOTHI  31  F  80  84  88  82  84  86  90  94  96     140  140  136  138  140  142  146  140  142       
16  TAMILSELVI  36  F  86  88  90  92  98  96  98           140  140  146  138  140  142  140             
17  SUMATHI  19  F  92  92  102  98  96  98              100  110  102  120  124  126                
18  SELVAJYOTHI  22  F  110  112  100  108  98  104  100           120  124  108  130  126  128  130  132          
19  POONGODI  16  F  102  110  108  100  98  104  110           90  112  100  104  116  118                
20  RANI  39  F  78  84  88  90  92  98  96           140  146  140  148  144  142  146             
21  VIJAYA  36  F  80  84  90  88  90  92  94           140  144  146  148  142  146  144             
22  PANCHU  42  F  98  90  99  100  92  102  98  100        140  140  140  136  140  142  140  142          
23  LALITHA  24  F  90  90  94  102  98  96              120  120  124  126  130  124                
24 
MATHULAKSH
MI  23  F  70  72  80  84  90  90  92           120  120  124  126  130  126  126             
25  CHITHRA  26  F  76  80  88  95  86  94              110  110  118  120  126  124                
26  AMUTHA  36  F  86  82  88  94  96  96  98           130  130  136  140  136  136  134             
27  DANAM  17  F  92  90  102  104  100  98              110  110  116  120  118  118                
28  NIRMALA  34  F  98  100  102  96  98  96  97           130  130  134  140  136  136  130             
29  NIRAIMATHI  42  M  82  84  98  94  88  96  98  88  86     140  140  146  144  142  146  150  146  142       
30  VALLI  32  F  74  76  80  86  90  96  88           130  130  134  136  134  136  134             
CONTROL SHEET 1 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                               CONTROL  SHEET 2 
SL 
NO  NAME  AGE  SEX 
DBP‐
PI 
DBP‐
1MIN 
DBP‐
5MIN 
DBP‐
15MIN 
DBP‐
30MIN 
DBP‐
45MIN 
DBP‐
60MIN 
DBP‐
75MIN 
DBP‐
90MIN 
DBP‐
105MIN 
FENTANY
L  
REQUIRE
MENT(MI
C) 
NO OF 
DOSES 
 OF 
ANTI‐ 
EMITIC 
SCORI
NG 
 OF N 
&V 
POST OP 
ANALGESIC
REQUIREM
ENT 
SEDATIO
N 
 SCORE‐
1HR 
SEDATI
ON 
 
SCORE‐
4HR 
SEDATIO
N 
 SCORE‐ 
6HR 
1  KUPPUSAMY  30  M  80  80  70  70  80  80  80  80  80     140  1  2  2  4  3  3 
2  SUBBIAH  34  M  90  80  80  90  90  90  86  86  84     120  NIL  1  3  3  2  2 
3  MANIARASU  45  M  90  84  90  90  90  90  90  90  90     120  1  2  2  2  2  2 
4  SREENIVASAN  32  M  90  86  90  90  90  90  90  90  90     120  1  2  3  3  2  2 
5  BALAKRISHNAN  28  M  90  84  84  90  86  90  86  86        120  1  2  2  2  2  2 
6  RAMU  34  M  80  80  90  86  80  90  86  90        120  1  2  2  2  2  2 
7  VELLAISAMY  25  M  80  86  80  84  80  80              120  1  2  2  1  2  2 
8  ARJUN  18  M  80  80  82  90  80  80  84  86  84     100  1  2  3  3  2  2 
9  MARUDUPANDI  34  M  80  84  84  90  86  88  86  90  86     140  1  2  3  4  2  2 
10  KARUPPIAH  24  M  70  80  84  84  90  80  80  80        120  1  2  2  2  2  2 
11  LOGESHWARI  17  F  70  78  80  80  80  84  82  82        100  1  2  2  2  2  2 
12  KASIAMMAL  21  F  80  82  84  90  86  88              100  1  2  2  2  2  2 
13  SELVI  18  F  80  82  80  84  84  82  84  90        120  1  2  3  1  2  2 
14  PREMA  21  F  80  82  80  84  86  86              100  1  2  2  2  2  2 
15  JYOTHI  31  F  80  80  84  86  90  88  82  86  86     120  1  2  3  3  2  2 
16  TAMILSELVI  36  F  90  90  86  90  86  90  90           120  2  3  3  2  2  2 
17  SUMATHI  19  F  70  74  68  78  80                 90  1  2  2  2  2  2 
18  SELVAJYOTHI  22  F  90  94  90  94  92  90  92  94        120  1  2  3  3  2  2 
19  POONGODI  16  F  70  74  78  80  78  80              80  1  2  2  2  2  2 
20  RANI  39  F  90  90  86  90  94  94  96           140  1  2  3  4  2  2 
21  VIJAYA  36  F  80  80  86  90  88  90  86           120  1  2  2  2  2  2 
22  PANCHU  42  F  80  80  88  84  86  88  90  86        120  1  2  3  2  2  2 
23  LALITHA  24  F  80  80  82  84  84  86              120  1  2  2  3  2  2 
24  MATHULAKSHMI  23  F  80  80  82  84  84  82  84           120  2  3  3  2  2  2 
25  CHITHRA  26  F  70  70  74  78  80  78              120  1  2  2  2  2  2 
26  AMUTHA  36  F  80  84  86  90  84  84  80           120  1  2  2  4  3  2 
27  DANAM  17  F  70  70  74  80  78  78              90  1  2  2  2  2  2 
28  NIRMALA  34  F  80  80  84  90  84  86  84           120  2  3  2  2  2  2 
29  NIRAIMATHI  42  M  80  80  84  84  86  90  84  84  84     140  1  2  3  3  2  2 
30  VALLI  32  F  80  80  82  84  84  84  84           120  1  2  2  3  2  2 
